Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.
To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this
Given the complex R&D protocols and the increasing demand for clinical evidence of therapeutic benefit, there seems to be a lucrative opportunity for contract research providers engaged in the medical devices’ domain. In fact, since 2000, 150 new CROs have been established that offer a variety of cost-efficient services and solutions to medical device developers.
To order this 400+ page report, which features 240+ figures and 200+ tables,
Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens that are generally overlooked during immune surveillance; these neoantigens have been shown to possess substantial therapeutic potential
London
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
Outsourcing the manufacturing of labels is a popular trend among medical device developers, enabling such companies to leverage the advanced capabilities of CMOs, while focusing on the core aspects of product development
To order this detailed 590+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of the medical device contract manufacturing market, featuring a list of CMOs engaged in this domain, and detailed analysis based on a number of relevant
To order this detailed 400+ page report, please visit thislink
Key Inclusions
A detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A] clinical
To order this detailed 350+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their
With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions
Roots Analysis is pleased to announce the publication of its recent study, titled, “
To order this detailed 350+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their
To order this 250+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies offering contract services for manufacturing of peptides, along with information on year of establishment, company size, scale of operation (
Roots Analysis has done a detailed study on Prefilled Syringes, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 800+ page report, which features 800+ figures and 150+ tables, please visit this ... Read more
A detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target
Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
To order this 530+ page report, which features ... Read more
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
To order this detailed 285+ page report, please visit thislink
Key Inclusions
A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of
Autoinjectors have become an important part of modern healthcare, having demonstrated the potential to address a number of parenteral drug delivery related adverse events, and improve medication adherence among patients
Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.
To order this 550+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies that are engaged in the manufacturing of cell-based therapies, including information on the type of cells manufactured (including immune cells (including T cells,
To order this detailed 250+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III
According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability. Further, these devices have proven to be useful in quarantining patients demonstrating symptoms of pleural wall thickening and lung congestion, a characteristic of pneumonia, as well as observed in patients suffering from the novel coronavirus (COVID-19).
Excessive capital requirement and myriad of other complexities associated with the discovery of biologics have prompted drug developers to adopt in silico tools / techniques to expedite the discovery timelines
Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs
Roots Analysis is pleased to announce the publication of its recent study, titled, “
Advancements in the domain of ophthalmology continue to expand the range of potential application areas for contact lenses. Presently, over 55 novel ophthalmic products have been developed or are being developed for the treatment of various ophthalmological disorders, diagnosis / monitoring of diseases and for restoring vision in the blind. The ongoing efforts to innovate in this domain are evident from the fact that more than 7,500 patents have been granted / filed since 2013.
